Phase 3 clinical trial of TROP2 targeting ADC/blockbuster PD-1 antibody for the first-line treatment of lung cancer is about to start

On October 25, 2021, Daiichi Sankyo and AstraZeneca jointly announced that they have reached a clinical trial cooperation and supply agreement with a subsidiary of MSD

Lung cancer is the world's second most common cancer and the leading cause of cancer-related deaths, with 80%-85% of NSCLC

TROP2 is a transmembrane glycoprotein that is widely expressed in several types of solid tumors, including NSCLC

▲Introduction to Dato-DXd (DS-1062) (picture source: Daiichi Sankyo official website)

Keytruda improves the anti-cancer response of human immune cells by blocking the PD-1/PD-L1 signaling pathway

This collaboration is based on the positive results of a Phase 1b clinical trial reached in May 2020 last year

Reference materials:

[1] Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with Keytruda® (pembrolizumab) in Patients with Metastatic Non-Small Cell Lung Cancer.